Published in Cancer Weekly, October 16th, 1995
Syncor will be responsible for distributing the products throughout North America and other countries where Syncor has radiopharmacies.
Gene McGrevin, Syncor president and CEO, said, "We believe our alliance with Neoprobe is a good corporate fit. The company's cancer targeting agents will be distributed to hospitals with radiopharmacies, and that is our area of expertise. We look forward to working with Neoprobe from product launch through building sales, as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.